RU2013102923A - Композиции норибогаина - Google Patents
Композиции норибогаина Download PDFInfo
- Publication number
- RU2013102923A RU2013102923A RU2013102923/15A RU2013102923A RU2013102923A RU 2013102923 A RU2013102923 A RU 2013102923A RU 2013102923/15 A RU2013102923/15 A RU 2013102923/15A RU 2013102923 A RU2013102923 A RU 2013102923A RU 2013102923 A RU2013102923 A RU 2013102923A
- Authority
- RU
- Russia
- Prior art keywords
- noribogaine
- composition
- ibogaine
- amount
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 37
- RAUCDOKTMDOIPF-UHFFFAOYSA-N hydroxyibogamine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-UHFFFAOYSA-N 0.000 claims abstract 26
- RAUCDOKTMDOIPF-RYRUWHOVSA-N noribogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-RYRUWHOVSA-N 0.000 claims abstract 26
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 claims abstract 14
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 claims abstract 14
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 claims abstract 14
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 claims abstract 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract 4
- BFLJLOKFWZLUTR-STGWVFMRSA-N noribogaine hydrochloride Chemical compound Cl.C([C@@H](C1)C[C@H]2CC)C3C2N1CCC1=C3NC2=CC=C(O)C=C12 BFLJLOKFWZLUTR-STGWVFMRSA-N 0.000 claims abstract 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000007530 organic bases Chemical class 0.000 claims abstract 2
- 239000000741 silica gel Substances 0.000 claims abstract 2
- 229910002027 silica gel Inorganic materials 0.000 claims abstract 2
- 239000007787 solid Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Композиция, содержащая норибогаин, в которой по меньшей мере 95% норибогаина находится в виде 2(R), 4(S), 5(S), 6(S) и 18(R) энантиомера и которая содержит не более 0,5 вес.% ибогаина по отношению к количеству норибогаина.2. Композиция по п.1, отличающаяся тем, что указанная композиция содержит не более 0,3 вес.% ибогаина по отношению к количеству норибогаина.3. Композиция по п.1, отличающаяся тем, что указанная композиция содержит не более 0,1 вес.% ибогаина по отношению к количеству норибогаина.4. Композиция по п.1, отличающаяся тем, что указанная композиция содержит менее 800 ppm ибогаина.5. Композиция по п.1, отличающаяся тем, что по меньшей мере 98% норибогаина находится в виде 2(R), 4(S), 5(S), 6(S) и 18(R) энантиомера.6. Композиция, содержащая норибогаин, в которой по меньшей мере 98% норибогаина находится в виде 2(R), 4(S), 5(S), 6(S) и 18(R) энантиомера и которая содержит не более 0,5 вес.% ибогаина по отношению к количеству норибогаина.7. Композиция по п.6, отличающаяся тем, что указанная композиция содержит не более 0,3 вес.% ибогаина по отношению к количеству норибогаина.8. Композиция по п.6, отличающаяся тем, что указанная композиция содержит не более 0,1 вес.% ибогаина по отношению к количеству норибогаина.9. Композиция, содержащая норибогаина гидрохлорид и изопропанол.10. Композиция, содержащая норибогаин, хлористоводородную кислоту в концентрации 5М и изопропанол, отличающаяся тем, что указанная композиция имеет температуру от 45 до 55°С.11. Композиция, содержащая норибогаин, силикагель, хлористый метилен, ацетонитрил и органическое основание.12. Композиция, содержащая твердый гидрохлорид норибогаина и изопропанол.
Claims (12)
1. Композиция, содержащая норибогаин, в которой по меньшей мере 95% норибогаина находится в виде 2(R), 4(S), 5(S), 6(S) и 18(R) энантиомера и которая содержит не более 0,5 вес.% ибогаина по отношению к количеству норибогаина.
2. Композиция по п.1, отличающаяся тем, что указанная композиция содержит не более 0,3 вес.% ибогаина по отношению к количеству норибогаина.
3. Композиция по п.1, отличающаяся тем, что указанная композиция содержит не более 0,1 вес.% ибогаина по отношению к количеству норибогаина.
4. Композиция по п.1, отличающаяся тем, что указанная композиция содержит менее 800 ppm ибогаина.
5. Композиция по п.1, отличающаяся тем, что по меньшей мере 98% норибогаина находится в виде 2(R), 4(S), 5(S), 6(S) и 18(R) энантиомера.
6. Композиция, содержащая норибогаин, в которой по меньшей мере 98% норибогаина находится в виде 2(R), 4(S), 5(S), 6(S) и 18(R) энантиомера и которая содержит не более 0,5 вес.% ибогаина по отношению к количеству норибогаина.
7. Композиция по п.6, отличающаяся тем, что указанная композиция содержит не более 0,3 вес.% ибогаина по отношению к количеству норибогаина.
8. Композиция по п.6, отличающаяся тем, что указанная композиция содержит не более 0,1 вес.% ибогаина по отношению к количеству норибогаина.
9. Композиция, содержащая норибогаина гидрохлорид и изопропанол.
10. Композиция, содержащая норибогаин, хлористоводородную кислоту в концентрации 5М и изопропанол, отличающаяся тем, что указанная композиция имеет температуру от 45 до 55°С.
11. Композиция, содержащая норибогаин, силикагель, хлористый метилен, ацетонитрил и органическое основание.
12. Композиция, содержащая твердый гидрохлорид норибогаина и изопропанол.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36731010P | 2010-07-23 | 2010-07-23 | |
| US61/367,310 | 2010-07-23 | ||
| US41976610P | 2010-12-03 | 2010-12-03 | |
| US61/419,766 | 2010-12-03 | ||
| PCT/US2011/045081 WO2012012764A1 (en) | 2010-07-23 | 2011-07-22 | Noribogaine compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013102923A true RU2013102923A (ru) | 2014-08-27 |
| RU2586296C2 RU2586296C2 (ru) | 2016-06-10 |
Family
ID=44558453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013102923/15A RU2586296C2 (ru) | 2010-07-23 | 2011-07-22 | Композиции норибогаина |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9358237B2 (ru) |
| EP (1) | EP2595632A1 (ru) |
| JP (2) | JP6049615B2 (ru) |
| CN (1) | CN103079571A (ru) |
| CA (1) | CA2806232A1 (ru) |
| MX (1) | MX2013000733A (ru) |
| RU (1) | RU2586296C2 (ru) |
| UA (1) | UA111065C2 (ru) |
| WO (1) | WO2012012764A1 (ru) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| WO2012012764A1 (en) | 2010-07-23 | 2012-01-26 | Demerx, Inc. | Noribogaine compositions |
| EP2481740B1 (en) * | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
| KR20140062472A (ko) * | 2011-09-15 | 2014-05-23 | 데메알엑스, 인크. | 노르이보가인 염 무용매화물 |
| EP2788003A4 (en) | 2011-12-09 | 2015-05-27 | Demerx Inc | PHOSPHATESTER OF NORIBOGAIN |
| CA2858820C (en) | 2012-01-25 | 2021-08-17 | Demerx, Inc. | Synthetic voacangine |
| WO2013112163A1 (en) * | 2012-01-25 | 2013-08-01 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| EP2807167A4 (en) * | 2012-01-25 | 2016-01-20 | Demerx Inc | INDOIND AND BENZO FURANKED ISOCHINUCLIDEN DERIVATIVES AND METHOD FOR THE MANUFACTURE THEREOF |
| US9150584B2 (en) | 2012-01-25 | 2015-10-06 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| JP2016508979A (ja) | 2012-12-20 | 2016-03-24 | デメレックス， インコーポレイテッド | 置換ノルイボガイン |
| WO2014143201A1 (en) | 2013-03-15 | 2014-09-18 | Demerx, Inc. | Method for noribogaine treatment of addiction in patients on methadone |
| WO2015126434A1 (en) * | 2014-02-18 | 2015-08-27 | Demerx, Inc. | Methods for acute and long-term treatment of drug addiction |
| US9561232B2 (en) | 2014-02-18 | 2017-02-07 | Demerx, Inc. | Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use |
| TW201534306A (zh) * | 2014-02-18 | 2015-09-16 | Demerx Inc | 使用降伊波加因（ｎｏｒｉｂｏｇａｉｎｅ）及相關化合物的治療方法 |
| US9591978B2 (en) | 2014-03-13 | 2017-03-14 | Demerx, Inc. | Methods and compositions for pre-screening patients for treatment with noribogaine |
| WO2015142346A1 (en) * | 2014-03-20 | 2015-09-24 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| CA2989550C (en) | 2014-06-18 | 2023-08-08 | Demerx, Inc. | Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them |
| US9549935B2 (en) | 2014-07-14 | 2017-01-24 | Demerx, Inc. | Methods and compositions for treating migraines using noribogaine |
| PT3223906T (pt) | 2014-11-26 | 2021-05-05 | Demerx Inc | Métodos e composições para potencializar a ação de analgésicos de opioides usando alcaloides de iboga |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CN113993522A (zh) | 2019-04-17 | 2022-01-28 | 指南针探路者有限公司 | 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法 |
| CA3144385A1 (en) * | 2019-06-24 | 2020-12-30 | Caamtech, Inc. | Ibogaine formulations |
| GB2620323A (en) * | 2019-07-15 | 2024-01-03 | Demerx Inc | Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids |
| WO2024145464A2 (en) * | 2022-12-29 | 2024-07-04 | Atai Therapeutics, Inc: | Ibogaine and noribogaine prodrugs and methods of use |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2877229A (en) | 1959-03-10 | Process for the manufacture of indoles | ||
| US2813873A (en) | 1957-11-19 | Derivatives of the ibogaine alkaloids | ||
| GB841697A (en) | 1956-03-22 | 1960-07-20 | Ciba Ltd | Analgesic compositions |
| US2823204A (en) * | 1956-03-30 | 1958-02-11 | Gobey Lab | Alkaloids of voacanga |
| GB924042A (en) | 1959-03-05 | 1963-04-18 | Geigy Ag J R | Process for the decarboxylation of alkyl esters of unsaturated, nitrogen-containing carboxylic acids |
| US3639408A (en) | 1967-06-03 | 1972-02-01 | Shionogi & Co | Process for the preparation of isoquinuclidine derivatives |
| US3516989A (en) | 1967-10-02 | 1970-06-23 | American Home Prod | Intermediates for total synthesis of iboga alkaloids and means of preparation |
| FR7131M (ru) | 1968-01-31 | 1969-07-21 | ||
| US3557126A (en) | 1969-08-14 | 1971-01-19 | American Home Prod | Derivatives of iboga alkaloids |
| US3574220A (en) | 1969-08-14 | 1971-04-06 | American Home Prod | 1,7-methano-1h-1-benzazepin-5(4h)-ones |
| CA982478A (en) | 1971-04-12 | 1976-01-27 | Jerome Berk | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
| US4375414A (en) | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
| US3715361A (en) | 1971-10-08 | 1973-02-06 | American Cyanamid Co | Acyl derivatives of 10-methoxyibogamine |
| US3875011A (en) | 1972-11-06 | 1975-04-01 | Syva Co | Enzyme immunoassays with glucose-6-phosphate dehydrogenase |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| FR2296418B1 (ru) | 1974-12-30 | 1978-07-21 | Anvar | |
| US4272541A (en) | 1978-06-02 | 1981-06-09 | Miles Laboratories, Inc. | 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them |
| AU7821581A (en) | 1980-12-17 | 1982-06-24 | Sterling Drug Inc. | Substitution of aromatic organic compounds |
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| CA1188989A (en) | 1981-05-21 | 1985-06-18 | Richard R. Scherschlicht | Nonapeptide for the treatment of drug withdrawal symptoms |
| US4604365A (en) | 1981-06-02 | 1986-08-05 | Electro-Nucleonics, Inc. | Immunoprecipitation assay |
| US4462941A (en) | 1982-06-10 | 1984-07-31 | The Regents Of The University Of California | Dynorphin amide analogs |
| US4499096A (en) | 1983-11-18 | 1985-02-12 | Lotsof Howard S | Rapid method for interrupting the narcotic addiction syndrome |
| US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
| US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
| GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| ATE95430T1 (de) | 1984-12-22 | 1993-10-15 | Sanol Arznei Schwarz Gmbh | Wirkstoffpflaster. |
| US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
| US4587243A (en) | 1985-07-15 | 1986-05-06 | Lotsof Howard S | Rapid method for interrupting the cocaine and amphetamine abuse syndrome |
| US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| US4857523A (en) | 1988-07-18 | 1989-08-15 | Nda International, Inc. | Rapid method for attenuating the alcohol dependency syndrome |
| US5629307A (en) | 1989-10-20 | 1997-05-13 | Olney; John W. | Use of ibogaine in reducing excitotoxic brain damage |
| US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| DE4010079A1 (de) | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| US5026697A (en) | 1990-05-30 | 1991-06-25 | Nda International, Inc. | Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome |
| US5152994A (en) | 1990-05-31 | 1992-10-06 | Lotsof Howard S | Rapid method for interrupting or attenuating poly-drug dependency syndromes |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5283247A (en) | 1991-02-06 | 1994-02-01 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
| US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
| US5290784A (en) | 1991-07-18 | 1994-03-01 | Yueqian Qu | Aconitane derivatives used as a medication to treat addiction |
| ES2123642T3 (es) | 1992-04-10 | 1999-01-16 | Merrell Pharma Inc | Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m. |
| FI945811L (fi) | 1992-06-12 | 1995-02-06 | Des Tyr Dynorphin Partnership | Des-Tyr-dynorfiinianalogeja |
| US5256669A (en) | 1992-08-07 | 1993-10-26 | Aminotek Sciences, Inc. | Methods and compositions for treating acute or chronic pain and drug addiction |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| EP0668764A1 (en) | 1992-09-21 | 1995-08-30 | QIN, Bo-yi | Methods for identifying and using low/non-addictive opioid analgesics |
| CN1042895C (zh) | 1992-09-23 | 1999-04-14 | 曲曰谦 | 治疗吸毒者戒断综合症及脱瘾的药物组合物 |
| WO1994014490A1 (de) | 1992-12-23 | 1994-07-07 | Bernhard Hugemann | Verfestigter arzneistoffvorrat für die mechanische erzeugung inhalierbarer wirkstoffpartikel |
| US5865444A (en) | 1994-03-21 | 1999-02-02 | Deere & Company | Body leveling suspension including a pivoting arrangement |
| JP2819236B2 (ja) | 1994-05-06 | 1998-10-30 | 日東電工株式会社 | 経皮吸収製剤 |
| US5552406A (en) | 1994-06-17 | 1996-09-03 | The Mclean Hospital Corporation | Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists |
| DK0804200T3 (da) | 1994-07-25 | 2006-09-11 | Nda Int Inc | Anvendelse af noribogain-derivater til behandling af kemisk afhængighed hos pattedyr |
| US5591738A (en) | 1994-10-14 | 1997-01-07 | Nda International, Inc. | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof |
| WO1997005869A1 (en) * | 1995-08-08 | 1997-02-20 | Albany Medical College | Ibogamine congeners |
| US5616575A (en) | 1995-12-04 | 1997-04-01 | Regents Of The University Of Minnesota | Bioactive tricyclic ibogaine analogs |
| US5760044A (en) | 1996-05-16 | 1998-06-02 | Archer; Sydney | Method for treating cocaine and amphetamine dependency |
| WO1997044317A2 (en) | 1996-05-21 | 1997-11-27 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Novel methods of o-demethylation and n-deprotection |
| US7220737B1 (en) | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
| CA2302754C (en) | 1997-09-04 | 2011-11-08 | Novoneuron, Inc. | Noribogaine in the treatment of pain and drug addiction |
| US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| WO2002100822A1 (en) | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| US20030153552A1 (en) | 2002-02-14 | 2003-08-14 | Mash Deborah C. | Method of treating chemical dependency in mammals and a composition therefor |
| US6864271B2 (en) | 2002-11-12 | 2005-03-08 | The Foundation For The Lsu Health Sciences Center | Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives |
| AU2004268594A1 (en) * | 2003-08-25 | 2005-03-10 | Cargill, Incorporated | Beverage compositions comprising monatin and methods of making same |
| US6806291B1 (en) | 2003-10-09 | 2004-10-19 | The Foundation For The Lsu Health Sciences Center | Analgesic compounds, their synthesis and pharmaceutical compositions containing them |
| US8017151B2 (en) | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
| CA2615581A1 (en) | 2005-07-26 | 2007-02-01 | Merckle Gmbh | Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase |
| ATE490237T1 (de) | 2005-08-26 | 2010-12-15 | Medical Res Council | Anionisch substituierte 7-nitroindol derivate und deren verwendung |
| BRPI0619268A2 (pt) | 2005-11-30 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal |
| EP1998766A2 (en) | 2005-12-16 | 2008-12-10 | Ironwood Pharmaceuticals, Inc. | Useful indole compounds |
| US9625475B2 (en) | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
| US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
| US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| US8637648B1 (en) | 2010-06-22 | 2014-01-28 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| WO2012012764A1 (en) | 2010-07-23 | 2012-01-26 | Demerx, Inc. | Noribogaine compositions |
| US8742096B2 (en) | 2011-03-28 | 2014-06-03 | Demerx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| KR20140062472A (ko) | 2011-09-15 | 2014-05-23 | 데메알엑스, 인크. | 노르이보가인 염 무용매화물 |
| JP6134094B2 (ja) | 2011-11-04 | 2017-05-24 | 株式会社神戸製鋼所 | 窒素酸化物の除去方法 |
| JP2015509076A (ja) | 2011-12-08 | 2015-03-26 | デメレックス， インコーポレイテッド | ノルイボガインの立体選択的全合成 |
| EP2788003A4 (en) | 2011-12-09 | 2015-05-27 | Demerx Inc | PHOSPHATESTER OF NORIBOGAIN |
| CA2908240A1 (en) | 2012-03-27 | 2013-10-03 | Albany Medical College | Blocking of cue-induced drug reinstatement |
| US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
| US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
-
2011
- 2011-07-22 WO PCT/US2011/045081 patent/WO2012012764A1/en not_active Ceased
- 2011-07-22 MX MX2013000733A patent/MX2013000733A/es unknown
- 2011-07-22 CN CN2011800381737A patent/CN103079571A/zh active Pending
- 2011-07-22 CA CA2806232A patent/CA2806232A1/en not_active Abandoned
- 2011-07-22 UA UAA201300802A patent/UA111065C2/ru unknown
- 2011-07-22 RU RU2013102923/15A patent/RU2586296C2/ru not_active IP Right Cessation
- 2011-07-22 US US13/383,405 patent/US9358237B2/en active Active
- 2011-07-22 JP JP2013520892A patent/JP6049615B2/ja active Active
- 2011-07-22 EP EP20110743404 patent/EP2595632A1/en not_active Withdrawn
-
2016
- 2016-06-03 US US15/173,587 patent/US20190262351A1/en not_active Abandoned
- 2016-11-22 JP JP2016226403A patent/JP6267776B2/ja active Active
-
2021
- 2021-03-16 US US17/202,985 patent/US20210275538A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013000733A (es) | 2013-05-30 |
| JP2013532663A (ja) | 2013-08-19 |
| JP2017061532A (ja) | 2017-03-30 |
| RU2586296C2 (ru) | 2016-06-10 |
| EP2595632A1 (en) | 2013-05-29 |
| US9358237B2 (en) | 2016-06-07 |
| WO2012012764A1 (en) | 2012-01-26 |
| CN103079571A (zh) | 2013-05-01 |
| US20190262351A1 (en) | 2019-08-29 |
| JP6267776B2 (ja) | 2018-01-24 |
| CA2806232A1 (en) | 2012-01-26 |
| JP6049615B2 (ja) | 2016-12-21 |
| US20130131046A1 (en) | 2013-05-23 |
| UA111065C2 (ru) | 2016-03-25 |
| US20210275538A1 (en) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013102923A (ru) | Композиции норибогаина | |
| EA201170742A1 (ru) | Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламинов и их применения | |
| MX2012003377A (es) | N-(1,2,5-oxadiazol-3-il)benzamidas y su utilizacion como herbicidas. | |
| EA201190306A1 (ru) | Улучшенная липидная композиция | |
| EA201100759A1 (ru) | Арилоазол-2-илцианоэтиламиносоединения противопаразитарного действия, обогащенные одним из энантиомеров | |
| EA201500653A1 (ru) | Композиции, содержащие триазольное соединение | |
| BR112013003332A2 (pt) | método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado | |
| EA201170772A1 (ru) | Органические соединения | |
| MA32811B1 (fr) | Nouveaux composés | |
| EA201490037A1 (ru) | Антагонисты trpv4 | |
| EA017249B8 (ru) | Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина | |
| EA201170680A1 (ru) | Ингибиторы акт и p70 s6-киназы | |
| EA201891754A1 (ru) | Композиции гиалуроновой кислоты, включающие мепивакаин | |
| BR112015009034A2 (pt) | método para a preparação de uma suspensão aquosa, suspensão aquosa, e, uso de uma suspensão aquosa | |
| WO2013072528A3 (en) | Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)pyridin-3-yl-carboxamide compounds and their use as herbicides | |
| MY194452A (en) | 1,4-Butanediol-Containing Composition | |
| EA201400822A1 (ru) | Производные гетероциклических амидов в качестве антагонистов p2xрецептора | |
| WO2010066810A8 (en) | Transdermal pharmaceutical compositions comprising a serm | |
| JO2770B1 (en) | Organic compounds | |
| UA113540C2 (xx) | Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду | |
| WO2012024397A3 (en) | 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | |
| MX356273B (es) | Estabilización de compuestos de yodo con polímeros de nitrógeno. | |
| EP3722277A3 (en) | 3'end caps for rna-interferring agents for use in rna | |
| EA201001842A1 (ru) | Новые соединения, обладающие активностью антагонистов мускариновых рецепторов | |
| EA201290228A1 (ru) | Соединение бензазепина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170723 |